News|Articles|June 26, 2026

5 Essential Capabilities for Decentralized Clinical Trials

Key Takeaways

Decentralized clinical trials are positioned as a foundational competency as clinical research continues shifting toward broader access and real-world evidence generation.
Expanded participation is enabled by reducing geographic and logistical barriers for patients, supporting more inclusive enrollment and retention.
Trial efficiency can improve through streamlined remote processes, but only when operational execution is intentionally designed for decentralization.
Successful delivery requires a comprehensive strategy addressing data integrity, compliance, participant experience, and coordinated technology-enabled workflows across distributed stakeholders.

As the clinical research landscape evolves, decentralized clinical trials (DCTs) have emerged as a foundational competency, enabling broader patient participation, increasing trial efficiency, and driving more inclusive, real-world data collection. However, the successful execution of DCTs requires more than just innovative technology—it demands a comprehensive strategy that addresses the unique challenges of decentralization.

Download Whitepaper

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

© FlowStudio - © FlowStudio - stock.adobe.com

October 26th, 2026

Measuring What Matters: Realigning Clinical Endpoints with Patient Reality

Patients don’t experience primary endpoints, so trials that stop at biomarkers and rigid rating scales risk declaring success while leaving daily burden untouched, and digital tools only deliver meaningful evidence when they are co-designed with patients and deployed with restraint.

© photon_photo - © photon_photo - stock.adobe.com

October 15th, 2026

Endpoints That Reflect What Patients Actually Value: Who Decides What Counts as Trial Success

Clinical trial endpoints define what success looks like, but patients and caregivers are rarely the ones setting that definition, and the gap between what trials measure and what patients actually value is showing up in post-approval evidence, regulatory submissions, and the design rooms where protocols are written.

October 15th, 2026

The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution

In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.

October 22nd, 2026

Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect

In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.

A new Syneos Health-Optum partnership aims to make trial timelines and costs more predictable. Credit: Stock.Adobe.com/wladimir1804

October 20th, 2026

Syneos Health, Optum Partner on Adaptive Clinical Development Model

Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.

A case study of how an emerging biotech moved from targeted monitoring to full clinical operations and site management across multiple studies. Credit: Stock.Adobe.com/PHOTO4U

October 12th, 2026

Flexible Clinical Operations and Site Management Across a Diversified Biotech Portfolio: An Application of Quality by Design and Risk-Based Oversight

How a phased CRO partnership built on ICH E6(R2) and E6(R3) principles supported a multi-indication biotech portfolio.

October 26th, 2026

How Much of the Community Participation Gap Is About Infrastructure, Not Willingness?

In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patient cost barriers and site infrastructure challenges must be solved together to close the participation gap in community and rural clinical trials.

Exploratory HERO data on ARD-101 in Prader-Willi syndrome arrive a day after FDA lifted the clinical hold, and Aardvark is planning a lower-dose Phase 3. Credit: Stock.Adobe.com/photon_photo

October 23rd, 2026

Aardvark Shares Data From Stopped Prader-Willi Trial as FDA Lifts Hold

Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.

5 Essential Capabilities for Decentralized Clinical Trials

Key Takeaways

Related to this article

Trending on Applied Clinical Trials Online

Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem

Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology

Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect

ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act

Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease